SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the month of June 2018

 

Commission File Number 001-38512

 

Oncolytics Biotech Inc. 

(Translation of registrant’s name into English)

 

Suite 210, 1167 Kensington Crescent NW

Calgary, Alberta, Canada T2N 1X7 

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F   þ

Form 40-F   o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   o

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   o

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

 

 

 

 

INCORPORATION BY REFERENCE

 

The Underwriting Agreement dated June 1, 2018 included as Exhibit 99.1 of this Form 6-K are incorporated by reference into the Registrant’s Registration Statement on Form F-10 (Commission File No333-224432).

 

EXHIBIT NUMBER		DESCRIPTION
99.1		Underwriting Agreement dated June 1, 2018

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

		Oncolytics Biotech Inc. (Registrant)
Date: June 1, 2018		By:		/s/  Kirk Look   Kirk Look Chief Financial Officer